Lexeo Therapeutics, Inc. Common Stock (LXEO) Financials
LXEO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 250.4 million | 18.9 million |
| Dec. 31, 2025 | 268.7 million | 22.0 million |
| Sept. 30, 2025 | 143.8 million | 23.0 million |
| June 30, 2025 | 176.1 million | 37.9 million |
LXEO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -21.2 million | 2.8 million |
| Dec. 31, 2025 | -20.1 million | 2.7 million |
| Sept. 30, 2025 | -29.8 million | 2.7 million |
| June 30, 2025 | -27.3 million | 3.1 million |
LXEO Net Income
No data available :(
LXEO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 71.8 million | 4.7 million | - |
| Dec. 31, 2025 | 181.8 million | - | 7.9 million |
| Sept. 30, 2025 | 41.0 million | 5.7 million | 8.5 million |
| June 30, 2025 | 132.9 million | - | 8.9 million |
LXEO Shares Outstanding
LXEO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 35000 | 15.7 million | 6.6 million | - |
| Dec. 31, 2025 | - | 16.2 million | 6.9 million | - |
| Sept. 30, 2025 | 289000 | 15.7 million | 6.0 million | - |
| June 30, 2025 | 108000 | 14.7 million | 16.0 million | - |
LXEO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 546000 |
| Dec. 31, 2025 | - | 538000 |
| Sept. 30, 2025 | - | 530000 |
| June 30, 2025 | - | 510000 |
LXEO
Price: $4.75
52 week price:
Earnings Per Share: -1.12 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 343.1 million